Mutual Of America Capital Management Lifted Sage Therapeutics (SAGE) Stake by $533,200 as Valuation Rose; Jpmorgan Chase & Co Com (JPM) Holder World Asset Management Has Cut Its Position

February 19, 2018 - By Peter Erickson

Mutual Of America Capital Management Llc increased its stake in Sage Therapeutics Inc. (SAGE) by 29.92% based on its latest 2017Q3 regulatory filing with the SEC. Mutual Of America Capital Management Llc bought 8,600 shares as the company’s stock rose 0.86% with the market. The institutional investor held 37,346 shares of the health care company at the end of 2017Q3, valued at $2.33M, up from 28,746 at the end of the previous reported quarter. Mutual Of America Capital Management Llc who had been investing in Sage Therapeutics Inc. for a number of months, seems to be bullish on the $7.39 billion market cap company. The stock decreased 0.75% or $1.23 during the last trading session, reaching $162.37. About 467,420 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since February 19, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

World Asset Management Inc decreased its stake in Jpmorgan Chase & Co Com (JPM) by 1.83% based on its latest 2017Q3 regulatory filing with the SEC. World Asset Management Inc sold 5,906 shares as the company’s stock declined 6.04% while stock markets rallied. The institutional investor held 316,486 shares of the major banks company at the end of 2017Q3, valued at $30.23M, down from 322,392 at the end of the previous reported quarter. World Asset Management Inc who had been investing in Jpmorgan Chase & Co Com for a number of months, seems to be less bullish one the $392.76B market cap company. The stock decreased 0.72% or $0.83 during the last trading session, reaching $114.68. About 13.21M shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since February 19, 2017 and is uptrending. It has outperformed by 17.04% the S&P500.

Among 33 analysts covering JPMorgan Chase & Co (NYSE:JPM), 18 have Buy rating, 2 Sell and 13 Hold. Therefore 55% are positive. JPMorgan Chase & Co had 110 analyst reports since July 21, 2015 according to SRatingsIntel. Nomura maintained JPMorgan Chase & Co. (NYSE:JPM) rating on Wednesday, February 24. Nomura has “Neutral” rating and $67 target. Jefferies maintained JPMorgan Chase & Co. (NYSE:JPM) rating on Wednesday, February 24. Jefferies has “Buy” rating and $67 target. As per Friday, August 28, the company rating was downgraded by Vetr. The company was maintained on Friday, October 6 by Citigroup. Macquarie Research downgraded JPMorgan Chase & Co. (NYSE:JPM) on Friday, September 9 to “Neutral” rating. On Tuesday, June 6 the stock rating was maintained by Keefe Bruyette & Woods with “Hold”. The stock has “Outperform” rating by Credit Suisse on Monday, July 17. Keefe Bruyette & Woods maintained JPMorgan Chase & Co. (NYSE:JPM) rating on Friday, July 14. Keefe Bruyette & Woods has “Hold” rating and $9400 target. Ertse Group downgraded the shares of JPM in report on Monday, April 25 to “Hold” rating. Berenberg initiated JPMorgan Chase & Co. (NYSE:JPM) on Wednesday, July 13 with “Sell” rating.

Since August 21, 2017, it had 1 insider buy, and 9 sales for $22.34 million activity. Lake Marianne sold $1.03M worth of stock or 9,194 shares. Friedman Stacey sold $902,608 worth of stock. CROWN JAMES S had bought 7,280 shares worth $825,327 on Tuesday, January 16. Giles Nicole sold $425,399 worth of JPMorgan Chase & Co. (NYSE:JPM) on Saturday, January 13. Scher Peter also sold $1.91 million worth of JPMorgan Chase & Co. (NYSE:JPM) on Saturday, January 13. $7.31 million worth of JPMorgan Chase & Co. (NYSE:JPM) was sold by Erdoes Mary E. on Saturday, January 13.

World Asset Management Inc, which manages about $17.12B and $3.02 billion US Long portfolio, upped its stake in Credit Suisse Group Ag Sponsor (NYSE:CS) by 27,015 shares to 150,105 shares, valued at $2.37M in 2017Q3, according to the filing. It also increased its holding in Bayer A G Sponsored Adr (BAYRY) by 145,598 shares in the quarter, for a total of 194,300 shares, and has risen its stake in Digital Rlty Tr Inc Com (NYSE:DLR).

Investors sentiment decreased to 0.91 in 2017 Q3. Its down 0.28, from 1.19 in 2017Q2. It is negative, as 65 investors sold JPM shares while 767 reduced holdings. 125 funds opened positions while 635 raised stakes. 2.50 billion shares or 7.05% less from 2.69 billion shares in 2017Q2 were reported. Country Fincl Bank owns 721,698 shares. Lazard Asset Ltd owns 979,393 shares or 0.19% of their US portfolio. Utd Fire Gru Inc accumulated 57,736 shares or 1.86% of the stock. Lsv Asset Mngmt holds 1.94% or 12.35 million shares. Park National Oh invested in 3.66% or 669,044 shares. Moreover, Mcf Limited Liability Company has 0.19% invested in JPMorgan Chase & Co. (NYSE:JPM) for 9,954 shares. Markston Int Ltd Com accumulated 1.4% or 143,230 shares. Jacobus Wealth Mngmt Inc reported 194,771 shares or 4.87% of all its holdings. The United Kingdom-based Lansdowne Ptnrs (Uk) Llp has invested 19.85% in JPMorgan Chase & Co. (NYSE:JPM). National Bank Of Hawaii stated it has 85,890 shares or 0.69% of all its holdings. Midwest Invest Management Ltd Liability Co holds 27,946 shares or 2.2% of its portfolio. Glaxis Management Llc reported 36,960 shares. Clarkston Capital Lc stated it has 5,803 shares. Glg Ptnrs Limited Partnership invested 0.05% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM). 23,946 were accumulated by Monarch Mgmt.

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics had 52 analyst reports since September 3, 2015 according to SRatingsIntel. Stifel Nicolaus maintained it with “Buy” rating and $91.0 target in Thursday, November 2 report. The stock has “Buy” rating by Cowen & Co on Tuesday, September 12. As per Wednesday, June 29, the company rating was initiated by BMO Capital Markets. RBC Capital Markets maintained it with “Buy” rating and $117.0 target in Monday, October 16 report. The company was maintained on Thursday, November 9 by BMO Capital Markets. The company was maintained on Thursday, October 19 by SunTrust. The firm earned “Buy” rating on Thursday, September 3 by JP Morgan. The stock has “Buy” rating by Cowen & Co on Thursday, November 9. The rating was maintained by Needham on Tuesday, September 12 with “Buy”. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given on Thursday, October 26 by BMO Capital Markets.

Since December 14, 2017, it had 0 buys, and 2 sales for $17.36 million activity. $7.80 million worth of stock was sold by Kanes Stephen on Wednesday, January 10.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>